Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-035 in locally advanced or metastatic breast cancer
NCT05160545Phase 1Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Multispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GNC-035 in breast cancer, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 2 weeks, Maximum Tolerated Dose at 2 weeks and 4 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
GNC-035
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05160545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160545.